Immunoglobulin M-mediated complement activation (IgM-mediated complement activation)

Immunoglobulin M-mediated complement activation refers to the process by which IgM antibodies, upon binding to antigens (typically on cell surfaces), initiate the activation of the complement system via the classical pathway. IgM is particularly efficient at triggering complement due to its pentameric or hexameric structure, which allows for multiple binding sites and easy engagement with the C1 complex (notably C1q), the first component of the classical pathway[2][4][5]. Upon antigen binding, IgM undergoes a conformational change, exposing binding sites for C1q. This interaction activates C1r and C1s, initiating a protein cleavage cascade that results in the deposition of C4b and downstream complement activation steps, including the formation of the membrane-attack complex (MAC)[2][3]. This process is central to host defense mechanisms—facilitating lysis of pathogens, clearance of immune complexes, and removal of apoptotic cells. However, inappropriate or mistargeted IgM complement activation can be pathologic, leading to conditions such as autoimmune hemolytic anemia, paroxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome[1][7]. Therapeutic strategies to block this pathway (e.g., complement inhibitors like eculizumab) have clinical applications but carry risks of impairing normal immune defense. Notably, "Immunoglobulin M-mediated complement activation" is a process, not a specific molecule or canonical druggable target, and for structured data would not be considered a discrete receptor, enzyme, or protein target[4][5].

Other names

IgM-dependent complement activationClassical complement pathway triggered by IgMIgM/complement interaction

Inhibition of complement cascade (by agents such as anti-C5 antibodies)